title: Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
abstract: Daclatasvir (DCV; BMS-790052) is a hepatitis C virus (HCV) NS5A replication complex inhibitor (RCI) with picomolar to low nanomolar potency and broad genotypic coverage in vitro. Viral RNA declines have been observed in the clinic for both alpha interferon-ribavirin (IFN-α-RBV) and IFN-RBV-free regimens that include DCV. Follow-up specimens (up to 6 months) from selected subjects treated with DCV in 14-day monotherapy studies were analyzed for genotype and phenotype. Variants were detected by clonal sequencing in specimens from baseline and were readily detected by population sequencing following viral RNA breakthrough and posttreatment. The major amino acid substitutions generating resistance in vivo were at residues M28, Q30, L31, and Y93 for genotype 1a (GT-1a) and L31 and Y93 for GT-1b, similar to the resistance substitutions observed with the in vitro replicon system. The primary difference in the resistance patterns observed in vitro and in vivo was the increased complexity of linked variant combinations observed in clinical specimens. Changes in the percentage of individual variants were observed during follow-up; however, the overall percentage of variants in the total population persisted up to 6 months. Our results suggest that during the 14-day monotherapy, most wild-type virus was eradicated by DCV. After the end of DCV treatment, viral fitness, rather than DCV resistance, probably determines which viral variants emerge as dominant in populations.
authors: Department of Virology, Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
authors: Chunfu
authors: C
authors: Wang
authors: Jin-Hua
authors: JH
authors: Sun
authors: Donald R
authors: DR
authors: O'Boyle
authors: Peter
authors: P
authors: Nower
authors: Lourdes
authors: L
authors: Valera
authors: Susan
authors: S
authors: Roberts
authors: Robert A
authors: RA
authors: Fridell
authors: Min
authors: M
authors: Gao
mesh_terms: D019943:Amino Acid Substitution; D000998:Antiviral Agents / Q000494:pharmacology*; D002219:Carbamates; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral / Q000187:drug effects* / Q000235:genetics; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D058889:Molecular Typing; D010641:Phenotype; D011759:Pyrrolidines; D012367:RNA, Viral / Q000037:antagonists & inhibitors* / Q000097:blood; D014633:Valine / Q000031:analogs & derivatives; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D012367:RNA, Viral; D014633:Valine; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase; C549273:daclatasvir
references: J Gen Virol. 2004 Nov;85(Pt 11):3173-3188
references: 15483230
references: Lancet Infect Dis. 2012 Sep;12(9):671-7
references: 22714001
references: J Virol. 2009 Jun;83(11):5760-4
references: 19321623
references: Hepatology. 2011 Dec;54(6):1924-35
references: 21809362
references: Nucleic Acids Res. 2007 Jan;35(Database issue):D363-6
references: 17142229
references: Nature. 2010 May 6;465(7294):96-100
references: 20410884
references: N Engl J Med. 2012 Jan 19;366(3):216-24
references: 22256805
references: J Virol. 2010 Jan;84(1):482-91
references: 19812153
references: J Viral Hepat. 2010 Dec;17(12):825-33
references: 20723038
references: Antimicrob Agents Chemother. 2012 Mar;56(3):1350-8
references: 22214777
references: Hepatology. 2012 Mar;55(3):742-8
references: 21987462
references: Hepatology. 2012 Jun;55(6):1692-9
references: 22234905
references: Antimicrob Agents Chemother. 2010 Sep;54(9):3641-50
references: 20585111
references: Hepatology. 2011 Dec;54(6):1956-65
references: 21837752